{"analyses":[{"ciLowerLimit":"0.57","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"1.06","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","pValue":"0.0574","paramType":"Hazard Ratio (HR)","paramValue":"0.78","statisticalMethod":"Regression, Cox"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"9.9","upperLimit":"16.3","value":"12.7"},{"groupId":"OG001","lowerLimit":"8.3","upperLimit":"13.7","value":"11.6"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"96"},{"groupId":"OG001","value":"98"}],"units":"Participants"}],"description":"Overall survival (OS) was defined as the time from randomization to death due to any cause.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants received pembrolizumab 200 mg IV every Q3W for up to 35 administrations (up to \\~2 years).","id":"OG000","title":"Pembrolizumab"},{"description":"Participants received capecitabine, eribulin, gemcitabine, or vinorelbine as single agent chemotherapy chosen by the treating physician (Treatment of Physician's Choice, TPC) in accordance with local regulations and guidelines.","id":"OG001","title":"Chemotherapy"}],"paramType":"MEDIAN","populationDescription":"All participants with PD-L1 CPS ≥10 who were included in a treatment group at randomization","reportingStatus":"POSTED","timeFrame":"Up to approximately 36 months (through Final Analysis database cutoff date of 11-April-2019)","title":"Overall Survival in Participants With Programmed Cell Death Ligand 1 (PD-L1) With Combined Positive Score (CPS) ≥10","type":"PRIMARY","unitOfMeasure":"Months"}